Facebook
Linkedin
Twitter
Industries
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Search
Friday, January 10, 2025
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
ReadMagazine
Industries
All
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Read Magazine’s Weekly News Roundup With Redwire, DXC, Ramp, Biofidelity, And…
A2 Biotherapeutics Secures $80M in Series C for Precision Cell Therapies
Quectel Achieves Gold Partner Status with NXP
LISNR Acquires Arden Labs to Enhance Proximity Engagement
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Home
Tags
Precision Cell Therapies
Precision Cell Therapies
Biotechnology
A2 Biotherapeutics Secures $80M in Series C for Precision Cell Therapies
News Desk
-
January 10, 2025
A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells,...
0
Fans
Like
3,912
Followers
Follow
0
Subscribers
Subscribe
Hot Topics
Read Magazine’s Weekly News Roundup With Redwire, DXC, Ramp, Biofidelity, And More!
A2 Biotherapeutics Secures $80M in Series C for Precision Cell Therapies
Quectel Achieves Gold Partner Status with NXP
Load more
